Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Ivacaftor“
Suchtreffer
Begriffe & Kennungen
Kalydeco · 4.5 · Ivacaftor may inhibit CYP2C9. Therefore, monitoring of the international normalised ratio (INR) is recommended
Eintrag öffnenKalydeco · 4.5 · Medicinal products affected by ivacaftor
Eintrag öffnenKalydeco · 4.5 · Medicinal products affecting the pharmacokinetics of ivacaftor
Eintrag öffnenKalydeco · 4.5 · Medicinal products affecting the pharmacokinetics of ivacaftor
Eintrag öffnenKalydeco · 4.5 · No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers.
Eintrag öffnenKalydeco · 4.5 · No dose adjustment is recommended when ivacaftor is used with moderate or weak CYP3A inducers.
Eintrag öffnenKalydeco · 4.5 · Potential for ivacaftor to interact with transporters
Eintrag öffnenKalydeco · 4.5 · Potential for ivacaftor to interact with transporters
Eintrag öffnenKalydeco · 4.8 · 14 placebo-treated patients, respectively. Two patients, one on placebo and one on ivacaftor permanently disco
Eintrag öffnenKalydeco · 4.8 · 16 Ivacaftor in a combination regimen with ivacaftor/tezacaftor/elexacaftor
Eintrag öffnenKalydeco · 4.8 · During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were
Eintrag öffnenKalydeco · 4.8 · During the 24-week, placebo-controlled, phase 3 study of ivacaftor/tezacaftor/elexacaftor, these figures were
Eintrag öffnenKalydeco · 4.8 · During the 48-week placebo-controlled studies 770-102 and 770-103 of ivacaftor as monotherapy in patients aged
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · During the placebo-controlled phase 3 studies (up to 24 weeks) of tezacaftor/ivacaftor, the incidence of maxim
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of maximum creatine phosphokinase > 5 x the ULN was 10.4% in ivacaftor/tezacaf
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of maximum creatine phosphokinase > 5 x the ULN was 10.4% in ivacaftor/tezacaf
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in ivacaftor/tezacaftor/e
Eintrag öffnenKalydeco · 4.8 · In study 445-102, the incidence of rash events (e.g., rash, rash pruritic) was 10.9% in ivacaftor/tezacaftor/e
Eintrag öffnenKalydeco · 4.8 · In study 770-108 ivacaftor was permanently discontinued in one patient. In study 770-124, in the cohort of pat
Eintrag öffnen